# Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

> **NCT02343718** · PHASE1 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 7 (actual)

## Conditions studied

- Recurrent Lymphoma
- Refractory Lymphoma
- Solid Tumours
- Central Nervous System

## Interventions

- **DRUG:** Vinblastine
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT02343718
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-24
- **Primary completion:** 2017-09-28
- **Final completion:** 2019-01-16
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343718, "Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02343718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*